The Structure of the Active Component of Hematoporphyrin Derivative
Photoradiation therapy (PRT) for local treatment of malignant tumors utilizing hematoporphyrin derivative (Hpd) as photosensitizing drug is undergoing clinical trials in several centers in the U. S. and abroad. This therapy is based on the localization and retention of Hpd in most tumors, as well as its photodynamic action which likely generates singlet oxygen at least as a first step. The only drug toxicity encountered to date in over 1500 patients receiving Hpd has been a generalized photosensitivity which requires patients to avoid bright light, especially sunlight, for 30 days or more. While this toxicity is avoidable it presents a drawback to utilizing PRT for early stage disease in ambulatory and active patients.
KeywordsHigh Performance Liquid Chromatography Fast Atom Bombardment Dimethyl Ester Generate Singlet Oxygen Methine Carbon
Unable to display preview. Download preview PDF.
- 3.T. J. Dougherty, D. G. Boyle, K. R. Weishaupt, B. A. Henderson, W. R. Potter, D. A. Bellnier and K. E. Wityk, Photoradiation therapy — Clinical and drug advances, in: “Porphyrin Photosensitization,” D. Kessel and T. J. Dougherty, eds., Plenum Publishing Corp., New York (1983).Google Scholar
- 4.D. Kessel and T. Chow, Tumor-localizing components of the porphyrin preparation hematoporphyrin derivative. Can. Res. 43:1994 (1983).Google Scholar
- 5.G. Levy, Private communication (1983).Google Scholar
- 6.R. L. Lipson, The photodynamic and fluorescent properties of a particular hematoporphyrin derivative and its use in tumor detection. Master’s Thesis, University of Minnesota (1960).Google Scholar
- 7.J. Moan and S. P. Sommer, Fluorescence and absorption properties of the components of hematoporphyrin derivative. Photobiochem. Photobiophys. 3:93 (1981).Google Scholar